

Epistatic interactions of *CDKN2B-TCF7L2* for risk of type 2 diabetes and of *CDKN2B-JAZF1* for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study

Ping An*, Mary Feitosa, Shamika Ketkar, Avril Adelman, Shio Lin, Ingrid Borecki and Michael Province

Address: Division of Statistical Genomics and Department of Genetics, Washington University School of Medicine (Campus Box 8506), 4444 Forest Park Boulevard, St. Louis, Missouri 63108, USA

E-mail: Ping An* - anping@wustl.edu; Mary Feitosa - mfeitosa@wustl.edu; Shamika Ketkar - sketkar@wustl.edu; Avril Adelman - avril@dsgmail.wustl.edu; Shio Lin - rosa@dsgmail.wustl.edu; Ingrid Borecki - iborecki@wustl.edu; Michael Province - mprovince@wustl.edu

*Corresponding author

from Genetic Analysis Workshop 16
St Louis, MO, USA 17-20 September 2009

Published: 15 December 2009

BMC Proceedings 2009, 3(Suppl 7):S71 doi: 10.1186/1753-6561-3-S7-S71

This article is available from: <http://www.biomedcentral.com/1753-6561/3/S7/S71>

© 2009 An et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Fifteen known type 2 diabetes (T2D) gene variants were assessed for their associations with T2D status in 228 T2D families from the Framingham Heart Study (FHS) Original, Offspring, and Children Cohorts. Bayesian approach was used to test single-single-nucleotide polymorphism (SNP) association followed by logistic regression. Bayesian and logic regression approaches were used to test multiple SNP association searching for the best combinations of variants followed by logistic regression reconfirmation. The significant variants for T2D risk were also tested for their main and interacting effects on triglyceride (TG)/high-density lipoprotein (HDL) ratio change derived from four point measures across time. This slope phenotype was made available using mixed model growth curve approach from 155 T2D families in the FHS Offspring Cohort.

Results: *CDKN2B* rs10811661 ($p = 0.042$), *TCF7L2* rs4506565 ($p = 0.004$), and *JAZF1* rs864745 ($p = 0.04$) were individually associated with risk of T2D (OR = 1.0-2.0; effect size <1%). *CDKN2B* and *TCF7L2* were found with significant main ($p = 0.02, 0.01$) and interacting ($p = 0.05$) effects for increased (OR = 3.0) risk of T2D. *CDKN2B* and *JAZF1* were found with significant main ($p = 0.0002$ and 0.034) and interacting ($p = 0.001$) effects on increased ($\beta = 0.42$) TG/HDL ratio longitudinal change. These interacting effects were independent of effects of age and sex with effect sizes of 0.3-0.4% for risk of T2D or TG/HDL ratio longitudinal change.

Conclusion: These synthetic approaches allowed for successful detection of *CDKN2B* and *TCF7L2* interacting effect for T2D risk and *CDKN2B* and *JAZF1* interacting effect on TG/HDL ratio increase over time among T2D families in the FHS. These interacting effects were consistent in conferring risk of T2D or progressive insulin resistance with modest effect sizes.

Background

Fifteen replicated gene variants for type 2 diabetes (T2D) have been assessed [1]. While more variants remain to be uncovered, challenge exists in better understanding of the interplay among these variants underneath complex T2D pathophysiology and pathogenesis. These variants were either common with negligible effect or rare with relatively larger effect size [1]. In reality, it is very likely that the individual main effect of each variant is undetectable, but collectively their effect emerges. Concurrent increased triglyceride (TG) and decreased high-density lipoprotein (HDL) were characteristics of subjects with insulin resistance, mostly seen in patients with T2D. The inverse relationship and combined information of these two measures, TG/HDL ratio, represents a single inherited phenotype [2] as a surrogate for insulin resistance [3]. In this analysis, we hypothesized that multiple variants jointly confer T2D susceptibility, and we wanted to examine main and interacting effects of the reported variants in the Offspring Cohort of the Framingham Heart Study (FHS) using different statistical analysis approaches.

Methods

Subjects

All participants in the FHS were Caucasians. Their characteristics were described elsewhere [4]. In brief, participants with diabetes comprised 7.59% (28/369), 9.91% (242/2,441), and 2.38% (95/3,997) of the Original, Offspring, and Children Cohorts, respectively. Average age of diagnosis of diabetes at study visit were 66, 57, and 46 years in the three cohorts, respectively. From a total of 6,807 members in 1,157 families, 228 families had members with diabetes (3,217 members, 366 diabetes cases); 46% (1,489/3,217) were men. In the Offspring Cohort, 155 families had members with diabetes (727 members) who had valid fasting TG and HDL measures at 4 time points. In the Offspring Cohort families with member with diabetes, the average age was 33.8, 46.4, 53.3, and 60.2 years, average BMI was 25.2, 26.2, 27.6, and 28.3 kg/m², average TG was 83.7, 108.5, 134.0, and 135.5 mg/dl, average HDL was 51.6, 52.6, 51.6, and 54.5 mg/dl, and average TG/HDL ratio was 1.9, 2.5, 3.1, and 3.0, at Visit 1, 3, 5, and 7, respectively. Every study subject provided written informed consent. The study was approved by Boston University Institutional Review Board.

Genotyping

Affymetrix 100 k single-nucleotide polymorphisms (SNPs) and genotype annotation resources were described elsewhere [4]. Identical variants or variants in the same intron/exon regions were identified using Affymetrix 500 k SNPs.

Statistical analysis

Covariates included age, age², and sex. BIMBAM (Bayesian imputation-based association mapping) [5] was used to assess single-SNP effect according to Bayes Factor (BF) and *p*-value (based on 10,000 permutations). This was followed by logistic-GEE (generalized estimating equations) single-SNP test under general and additive assumptions. BIMBAM output corrected *p* for multiple testing. BIMBAM was further used to identify the best multiple-SNP combination with the highest BF. LOGREG [6] was also used to find the best multiple SNP combination as well as parameter estimates. Findings from these two approaches were compared. The best interacting variants may be tested for main and interacting effects using the logistic-GEE approach. Further, TG/HDL ratios at the four visits in the families in the Offspring Cohort with member with diabetes were used to derive TG/HDL ratio change (slope) via the mixed growth curve model. The mixed sandwich estimator approach was used to assess associations between the identified interacting variants and the slope phenotype.

Results

Single-SNP test results are presented in Table 1 (BIMBAM) and Table 2 (logistic-GEE, general model). Three variants were found to significant under additive assumption: *CDKN2B* rs10811661 (*p* = 0.0011), *TCF7L2* rs4506565 (*p* = 0.0043), and *JAZF1* rs864745 (*p* = 0.0402). Multiple SNP test results are also given in Table 1. LOGREG results, consistent with the BIMBAM finding, suggested almost the same best interacting variants. Interaction between *CDKN2B* rs10811661 and *TCF7L2* rs4506565 was significantly detected using the logistic-GEE model (OR = 3.0, *p* = 0.02 and 0.01 and 0.05 for main and interacting effects). For the slope trait, single-SNP test results were non-significant for *CDKN2B* rs10811661 (*p* = 0.4621), but significant for *TCF7L2* rs4506565 (*p* = 0.0379) and *JAZF1* rs864745 (*p* = 0.0349) in the mixed sandwich estimator additive model. Interaction between *CDKN2B* rs10811661 and *TCF7L2* rs4506565 variants were significant (β = 1.6667, *p* = 0.0002, 0.0341, and 0.0012 for main and interacting effects), and it was associated with high slope values, which may be expressed as an increase in insulin resistance across ages.

Discussion

Our finding of *TCF7L2* intron 3 variant for T2D is in line with a previous FHS genome-wide association study report [7] and a good number of replicating reports across large and independent study cohorts. Evidence of *CDKN2B* near/promoter and *JAZF1* intron 1 variants for T2D risk was also found. We thought the T2D families in FHS may contain an enriched genetic component for SNP association assessment of T2D gene variants. Currently, functions

Table 1: Search results for best single and multiple SNP associations with T2D status

Method	Gene	Chr	Position	RAF ^a	Bayes Factor	Rank	p ^b
BIMBAM							
rs10811661	CDKN2A/2B	9p	22124094	T, 0.82	0.978	1	0.0045
rs4506565	TCF7L2	10q	114748339	T, 0.36	0.591	2	0.0154
rs864745	JAZF1	7p	28147081	A, 0.52	0.041	3	0.0397
rs17030946	THADA	2p	43587013	T, 0.10	0.035	4	0.0771
rs7961581	TSPAN8-LGR5	12q	69949369	T, 0.70	-0.161	5	0.1298
rs10946398	CDKAL1	6p	20769013	C, 0.33	-0.284	6	0.2382
rs5215	KCNJ11	11p	17365206	C, 0.36	-0.292	7	0.0944
rs2793823	ADAM30	1p	120239241	G, 0.89	-0.366	8	0.4292
rs10282940	SLC30A8	8q	118257007	G, 0.89	-0.381	9	0.4606
rs5018648	WFS1	4p	6343719	G, 0.61	-0.457	10	0.2901
rs8050136	FTO	16q	52373776	A, 0.41	-0.457	11	0.4008
rs1801282	PPARG	3p	12368125	G, 0.11	-0.488	12	0.8047
rs564398	CDKN2A/2B	9p	22019547	G, 0.39	-0.517	13	0.5119
rs4402960	IGF2BP2	3q	186994381	G, 0.67	-0.601	14	0.4523
rs4607103	ADAMTS9	3p	64686944	C, 0.74	-0.613	15	0.8136
SNP pair 1	-	-	-	-	1.76	1, 2	-
SNP pair 2	-	-	-	-	1.064	1, 3	-
LOGREG							
rs864745	JAZF1	7p	28147081	A, 0.52	0.03 (tree 1)	Rec	and
rs10811661	CDKN2A/2B	9p	22124094	T, 0.82	0.09 (tree 2)	Rec	and
rs4506565	TCF7L2	10q	114748339	T, 0.36	0.09 (tree 2)	Dom	and
rs5215	KCNJ11	11p	17365206	C, 0.36	0.09 (tree 2)	Dom	or

^aRAF, risk allele and frequency.

^bPermutation-based p-values for single-SNP association tests with T2D status using BIMBAM.

^cRec, recessive coding; Dom, dominant coding.

of these two genes are yet not clear, but as is the case for *TCF7L2* and other confirmed T2D genes [1], they may be directly or indirectly involved in pancreatic β -cell failure, insulin resistance, and lipid toxicity. Our finding of interactions among the three variants for T2D risk was interesting and novel, which may help disentangle underlying gene pathways and further our understanding of T2D etiology and pathophysiology.

Correction for multiplicity to minimize the false-positive declaration rate seems to be less sensitive for this analysis for two reasons. First, we aimed to identify and evaluate the best combination of SNPs from confirmed T2D variants. Second, the FHS T2D status information was obtained at the initial visit of the study, and 'new' T2D cases may have remained in the 'non-diabetic' control group after decades of follow-up. This would bias our association findings towards reduction of type 1 error. The results of BIMBAM were consistent with those of logistic-GEE analyses for the single-SNP main effect; likewise, BIMBAM and logic regression results for multiple-SNP joint/interacting effect were also consistent. These synthetic approaches apparently worked well in association detection for both main and joint effects of candidate gene variants with prior knowledge.

This 500 k SNP genotype data allowed us to examine 15 of the 18 confirmed exact variants (genotypic

imputation was not applied). While reproducibility may be cohort-specific and sensitive to sample heterogeneity and size, it was a bit surprising that we could only identify three meaningful variants. It is very possible that this was due to the presence in the control groups of persons with diabetes who had not received a clinical diagnosis. We did not use a transmission-disequilibrium test-like FBAT program for this analysis simply because we wanted to maximize the sample size by using all available family information. We did not correct the data for potential effect of body mass index because obesity coexisting with T2D is very likely rooted in the same pathway genes among most T2D patients, at least in most Western countries.

We were excited to find that the identified interacting variants also affected the TG/HDL ratio. Using the ROC/AUC (receiver operator characteristic/area under the curve) model, we found that it was an imperfect predictor of T2D with best sensitivity and specificity of approximately 75%. Applying a mixed growth curve approach to model longitudinal multiple measures of the TG/HDL ratio proved useful. The derived slope phenotype represented the TG/HDL ratio change across decades of observation time. This approach is advantageous in handling missing data points, as well as remote values, especially in intervention and interaction studies. Genetic heritability of the slope phenotype was 20%,

Table 2: Single-SNP association test results for T2D status confirmed by regression analysis

SNP	Gene	Chr	Position	RAF	OR (95% CI)	R ²	P ^a
rs2793823	ADAM30	1p	120239241	G, 0.89	2.0 (0.3-13.0) 2.2 (0.4-14.1)	0.0007	0.4762 0.3905
rs17030946	THADA	2p	43587013	T, 0.10	1.2 (0.3-5.2) 0.8 (0.5-1.2)	0.0044	0.793 0.2617
rs4607103	ADAMTS9	3p	64686944	C, 0.74	1.1 (0.6-2.1) 1.1 (0.6-2.1)	0.0002	0.6784 0.3905
rs1801282	PPARG	3p	12368125	G, 0.11	1.2 (0.1-28.7) 0.9 (0.6-1.3)	0.0004	0.8895 0.625
rs4402960	IGF2BP2	3q	186994381	G, 0.67	1.2 (0.8-2.0) 1.2 (0.7-1.9)	0.0014	0.3728 0.5386
rs5018648	WFS1	4p	6343719	G, 0.61	1.1 (0.7-1.6) 1.0 (0.6-1.4)	0.0017	0.8127 0.8432
rs10946398	CDKALI	6p	20769013	C, 0.33	1.2 (0.7-2.1) 1.3 (0.9-2.1)	0.0014	0.4013 0.1858
rs864745	JAZF1	7p	28147081	A, 0.52	1.5 (1.0-2.3) 1.1 (0.8-1.6)	0.0043	0.0427^b 0.6146
rs10282940	SLC30A8	8q	118257007	G, 0.89	1.3 (0.4-4.5) 1.3 (0.4-4.3)	0.0006	0.6785 0.7141
rs10811661	CDKN2A/2B	9p	22124094	T, 0.82	2.1 (1.0-4.4) 1.3 (0.6-2.9)	0.0061	0.0424 0.4428
rs564398	CDKN2A/2B	9p	22019547	G, 0.39	1.1 (0.7-1.9) 1.0 (0.8-1.4)	0.0007	0.5892 0.7728
rs4506565	TCF7L2	10q	114748339	T, 0.36	2.0 (1.2-3.1) 1.4 (0.9-2.0)	0.0045	0.0041 0.0932
rs5215	KCNJ11	11p	17365206	C, 0.36	1.0 (0.6-1.7) 0.7 (0.5-1.0)	0.0039	0.9201 0.0619
rs7961581	TSPAN8-LGR5	12q	69949369	T, 0.70	1.1 (0.7-1.8) 1.3 (0.8-2.2)	0.0024	0.6417 0.2377
rs8050136	FTO	16q	52373776	A, 0.41	1.1 (0.7-1.7) 0.9 (0.7-1.2)	0.001	0.6854 0.6667

^aLogistic-GEE regression *p* for genotypes homozygous (line 1) and heterozygous (line 2) for a risk allele with genotype homozygous for a non-risk allele as reference.

^bBold font indicates significant *p*-values.

and these three variants were individually and interactively associated with an increase of the slope phenotype. Previously, it was thought that the *TCF7L2* variant was only associated with β -cell function failure but not insulin resistance [1]. Our current finding suggests that *TCF7L2*, together with *JAZF1* variants, may indirectly impart insulin resistance through joint modulation of lipid metabolism.

In conclusion, using the FHS T2D family data and different statistical approaches, we found variants in the *TCF7L2*, *CDKN2B*, and *JAZF1* genes were independently and interactively associated with increased T2D risk and the TG/HDL ratio change across ages. For the remaining T2D risk conferring gene variants, we did not find significant association evidence in this analysis.

List of abbreviations used

AUC: Area under the curve; BF: Bayes factor; BIMBAM: Bayesian imputation-based association mapping; GAW16: Genetic Analysis Workshop 16; GEE: Generalized-estimating equations; HDL: High-density lipoprotein; TG: Triglyceride; T2D: Type 2 diabetes; FHS:

Framingham Heart Study; ROC: Receiver operator characteristic; SNP: Single-nucleotide polymorphism;

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PA, MF, IB, and MP drafted the manuscript. SK, AA, and SL performed the statistical data analysis. All authors read and approved the final manuscript.

Acknowledgements

The Genetic Analysis Workshops are supported by NIH grant R01 GM031575 from the National Institute of Health and General Medical Sciences.

This article has been published as part of *BMC Proceedings* Volume 3 Supplement 7, 2009: Genetic Analysis Workshop 16. The full contents of the supplement are available online at <http://www.biomedcentral.com/1753-6561/3?issue=S7>.

References

1. Lango H, UK Type 2 Diabetes Genetics Consortium, Palmer CN, Morris AD, Zeggini E, Hattersley AT, McCarthy MI, Frayling TM and Weedon MN: **Assessing the combined impact of 18 common**

- genetic variants of modest effect sizes on type 2 diabetes risk.** *Diabetes* 2008, **57**:3129–3135.
2. Mahaney MC, Blangero J, Comuzzie AG, VanderBerg JL, Stern MP and MacCluer JW: **Plasma HDL cholesterol, triglycerides, and adiposity. A quantitative genetic test of the conjoint trait hypothesis in the San Antonio Family Heart Study.** *Circulation* 1995, **92**:3240–3248.
 3. Kannel WB, Vasani RS, Keyes MJ, Sullivan LM and Robins SJ: **Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort).** *Am J Cardiol* 2008, **101**:497–501.
 4. Cupples LA, Arruda HT, Benjamin EJ, D'Agostino RB Sr, Demissie S, DeStefano AL, Dupuis J, Falls KM, Fox CS, Gottlieb DJ, Govindaraju DR, Guo CY, Heard-Costa NL, Hwang SJ, Kathiresan S, Kiel DP, Laramie JM, Larson MG, Levy D, Liu CY, Lunetta KL, Mailman MD, Manning AK, Meigs JB, Murabito JM, Newton-Cheh C, O'Connor GT, O'Donnell CJ, Pandey M, Seshadri S, Vasani RS, Wang ZY, Wilk JB, Wolf PA, Yang Q and Atwood LD: **The Framingham Heart Study 100 K SNP genome-wide association study resource: overview of 17 phenotype working group reports.** *BMC Med Genet* 2007, **8**(Suppl 1):S1.
 5. Servin B and Stephens M: **Imputation-based analysis of association studies: candidate regions and quantitative traits.** *PLoS Genetics* 2007, **3**:e114.
 6. Ruczinski I, Kooperberg C and Le Blanc ML: **Logic regression.** *J Comput Graph Stat* 2003, **12**:475–511.
 7. Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA and Dupuis J: **Genome-wide association with diabetes-related traits in the Framingham Heart Study.** *BMC Med Genet* 2007, **8**(Suppl 1):S16.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

